STARPHARMA (SPHRY)

[flemsnopes]

Starpharma Holdings Limited : Cleansing Statement
Notice under section 708A(5)(e) of the Corporations Act 2001 Melbourne, Australia; 21 November 2011:
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) (Starpharma) is pleased to announce that it has issued 29,767,442 fully paid ordinary shares (Shares) to institutional, sophisticated and professional investors in accordance with the private placement announced to ASX on 16 November 2011.
Starpharma gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

• Starpharma issued the Shares without disclosure to investors under Part 6D.2 of the

Corporations Act.

• As at the date of this notice, Starpharma has complied with:

o the provisions of Chapter 2M of the Corporations Act as they apply to Starpharma;

and

o section 674 of the Corporations Act.

• As at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

Ben Rogers

Company Secretary

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of

dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on

SPL's

dendrimer technology are already

on the market in the form of diagnostic elements and

laboratory reagents through licence arrangements with partners including Siemens and Merck KGaA.

The Company's lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV, genital herpes and bacterial vaginosis. Starpharma has a licence agreement with Ansell Limited to develop a VivaGel®-coated condom, and a licence agreement with Okamoto Industries Inc in relation to the VivaGel®-coated condom for the Japanese market. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

Starpharma also has agreements in place with Lilly, Elanco, Stiefel Laboratories (a GSK Company), and Siemens Healthcare as well as many research collaborations with some of the world's leading organisations in the fields of pharmaceuticals, drug delivery, cosmetics and agrochemicals.

A dendrimer is a type of precisely-defined, branched nanoparticle. the medical, electronics, chemicals and materials industries.

Dendrimers have applications in

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code SPHRY (CUSIP number
855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). Starpharma's ADRs are listed on International OTCQX, a premium market tier in the U.S. for international exchange-listed companies.

Media: Buchan Consulting
Rebecca Wilson

Mob: [phone]

[e-mail]